Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk Stock Rises as Wegovy Pill Hits the U.S. Market
12:28pm, Monday, 05'th Jan 2026
Novo Nordisk (NVO) climbed about 2% on Monday morning after launching an oral version of its blockbuster weight-loss drug Wegovy, priced at $149 a month for 1.5
Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost
12:23pm, Monday, 05'th Jan 2026
Novo Nordisk A/S (NYSE: NVO) on Monday said the Wegovy pill is now available, which was approved in December 2025.
Novo Nordisk launches first oral GLP-1 weight loss pill in the US
11:40am, Monday, 05'th Jan 2026
Novo Nordisk (NYSE:NVO) has made its Wegovy pill, the first oral GLP-1 treatment for weight loss, broadly available to patients in the United States. The launch marks a new development in obesity trea
China Market Unsettled, But Novo Nordisk's Oral Wegovy May Keep Revenue On Track
11:31am, Monday, 05'th Jan 2026
Novo Nordisk A/S launches oral Wegovy in the U.S. at aggressive introductory pricing, aiming to secure early market share and first-mover advantage. NVO faces imminent semaglutide patent expiry in Chi
Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.
10:57am, Monday, 05'th Jan 2026
Novo Nordisk's wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the U.S.
Exclusive: Novo Nordisk's US public affairs head leaves company
09:53am, Monday, 05'th Jan 2026
Danish obesity drugmaker Novo Nordisk's head of public affairs in the U.S. has left the company, according to an internal memo seen by Reuters, at a time when the firm is battling to revive its fortun
Novo Nordisk Launches Wegovy™ Pill, Expanding Patient Choice and Access With knownwell as a Recognized NovoCare® Provider
09:40am, Monday, 05'th Jan 2026
BOSTON--(BUSINESS WIRE)--Novo Nordisk today announced the U.S. launch of the Wegovy™ pill, the first oral GLP-1 option approved by the Food and Drug Administration for chronic weight management. The
Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?
09:35am, Monday, 05'th Jan 2026
Novo Nordisk's FDA-approved Wegovy pill marks the first oral GLP-1 weight loss therapy, aiming to revive momentum and reshape competition in 2026.
Novo Nordisk's Wegovy Pill Now Broadly Available Across U.S.
08:42am, Monday, 05'th Jan 2026
Novo Nordisk's Wegovy weight-loss pill is now broadly available across the U.S., two weeks after it received U.S. regulatory approval, the Danish drugmaker said.
UK's pharma regulator could issue a decision for Novo's Wegovy pill by year-end
08:08am, Monday, 05'th Jan 2026
Britain's medicines regulator said on Monday it was reviewing Novo Nordisk's application for an oral 25 milligram version of its weight-loss drug Wegovy and anticipated making a decision before the en
First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
08:00am, Monday, 05'th Jan 2026
American patients can now receive the first-ever GLP-1 pill for weight loss from Novo Nordisk, marking a new chapter of obesity treatment in the U.S. The cash prices of the drug, called the Wegovy p
Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America
08:00am, Monday, 05'th Jan 2026
Average weight loss of ~17% if all patients stayed on treatment* with Wegovy® (semaglutide) tablets 25 mg (~14% regardless of if patients stayed on treatment**) in the OASIS 4 trial1 Starting dose of
Novo Nordisk to Sell Wegovy Pill in U.S. Starting at $149 per Month
07:07am, Monday, 05'th Jan 2026
Novo Nordisk (NVO, Financials) announced on Monday that it would start selling its oral Wegovy weight loss tablet in the US for $149 a month for those who pay f
Crypto ETPs defy market weakness, post $164B in AUM for 2025: Fineqia analysis
06:53am, Monday, 05'th Jan 2026
Global digital asset Exchange Traded Products (ETPs) ended 2025 on a high note, with total assets under management (AUM) rising 8.8% to $164.2 billion...
Novo Nordisk launches first oral GLP-1 weight loss pill in the US
06:35am, Monday, 05'th Jan 2026
Novo Nordisk (NYSE:NVO) has made its Wegovy pill, the first oral GLP-1 treatment for weight loss, broadly available to patients in the United States. The...
